Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease classification and the economics of biologics, real-world outcomes in atopic dermatitis and psoriasis, and a cluster of practical papers on infection, hair loss, and melanocytic lesion surveillance. Let's dive in. We'll start with two papers in JAMA Dermatology that tackle very different…

This week's papers:

Pyoderma Gangrenosum Phenotype Classification — JAMA Dermatology 2026
Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa — JAMA Dermatology 2026
Treatment of tinea capitis in China: a multicenter prospective real-world study — Journal of the American Academy of Dermatology 2026
Risk-adapted monitoring of melanocytic lesions with peripheral globules: a longitudinal cohort study on melanoma risk stratification — Journal of the American Academy of Dermatology 2026
Systemic Comorbidities in Central Centrifugal Cicatricial Alopecia: A Systematic Review and Meta-analysis — Acta Dermato-Venereologica 2026
Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast — Dermatology 2026
Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study — Clinical and Experimental Dermatology 2026
Staphylococcal Scalded Skin Syndrome Often Does Not Require Empiric Coverage for Methicillin Resistance — Pediatric Dermatology 2026
Early Clinical Response Predicts Treatment Persistence in Advanced Therapy-naive Atopic Dermatitis — Acta Dermato-Venereologica 2026
Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry — Acta Dermato-Venereologica 2026